Semaglutide study reveals long-term effects on caloric intake

A 60-week study conducted by American scientists has revealed new insights into the long-term effects of semaglutide on weight loss and appetite. The research, involving 120 adults with overweight or obesity, found that participants using semaglutide consumed an average of 270 kcal fewer during a controlled meal compared to the placebo group after one year.

While the medication significantly reduced perceived hunger during the initial stages of treatment, the difference in subjective appetite became statistically insignificant by weeks 40 and 60. Despite the stabilization of hunger levels, caloric intake remained lower, and the semaglutide group saw an average weight loss of 15.4 kg, compared to 3.6 kg in the placebo group.

Medical experts emphasize that GLP-1 analogues, such as semaglutide and liraglutide, are tools to assist in managing obesity rather than replacements for lifestyle changes. Effective treatment requires a combination of pharmacological intervention, nutritional adjustments, physical activity, and psychological support. This is particularly critical in pediatric cases, where obesity affects approximately one in four children aged seven to nine in Europe.